Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Document Type
Year range
1.
Vacunas (English Edition) ; 2022.
Article in English | EuropePMC | ID: covidwho-1863812

ABSTRACT

Objective Colombia designed and adopted a vaccination plan against COVID-19 that will immunize 35 million people. The study aim was to detect the level of willingness to accept vaccination against COVID-19. Methods A telephone survey of 11,721 people aged 80 and over, affiliated with a health insurer, was carried out. The respondents were the affiliates or their relatives or caregivers. Results The average age was 85.0 years (SD: 4.5), with no differences between sexes;3,344 (28.5%) referred to a previous diagnostic test for COVID-19 and 73 were positive, giving an incidence of 622.8 per 100,000 people (95% CI: 491-778). Regarding attitude to vaccination against SARS-CoV-2, 1/4 respondents refrained from giving an opinion or were neutral. When the respondent was a relative, the acceptance of the vaccine was 60.4% (95% CI: 59.5-61.3) with differences by gender: men 62.2% (95% CI: 60.8-63.6) and women 59.2 (95% CI: 58.0-60.3), P < .05. When the respondent was the potential recipient of the vaccine, the acceptance of the vaccine was 61.7% (95% CI: 59.4-64.0) and this also differed by gender: 70.2% in men (95% CI: 66, 9-73.5) and 55.1% in women (95% CI: 52.0-58.3), P < .05. Conclusion The relatively low acceptance of vaccination against COVID-19 in Colombia poses significant challenges to achieve herd immunity that would allow control of the pandemic.

2.
Vacunas (English Edition) ; 2022.
Article in English | ScienceDirect | ID: covidwho-1852219

ABSTRACT

Resumen Objetivo Colombia diseñó y adoptó un plan de vacunación contra la COVID-19. El objetivo de esta investigación fue conocer la disposición para aceptar la vacunación contra esa enfermedad de personas de 80 y más años. Métodos Se realizó una encuesta telefónica a 11.721 personas de 80 y más años, afiliadas a una aseguradora de salud, en la que se indagó sobre la intención a recibir la vacuna. Los respondientes fueron los afiliados o sus familiares o cuidadores. Resultados El promedio de edad fue 85,0 años (SD: 4,5), sin diferencias entre sexos;3.344 participantes (28,5%) refirieron el antecedente de haberse realizado una prueba diagnóstica previa de COVID-19 y 73 resultaron positivos. La incidencia acumulada de infección por SARS-CoV-2 desde marzo de 2020 fue de 622,8 por 100.000 personas (IC95%: 491-778 por 100.000). Respecto a la actitud hacia la vacunación contra la COVID-19, uno de cada 4 respondientes se abstuvo de opinar o se manifestó neutro. Cuando el respondiente era un familiar, la aceptación de la vacuna era del 60,4% (IC95%: 59,5-61,3) con diferencias por sexo: entre los hombres era del 62,2% (IC95%: 60,8-63,6) y en mujeres del 59,2 (IC95%: 58,0-60,3), con p<0,05. Cuando el respondiente fue el potencial receptor de la vacuna, la aceptación de la vacuna fue del 61,7% (IC95%: 59,4-64,0) y también difería por sexos: 70,2% en hombres (IC95%: 66,9-73,5) y 55,1% en mujeres (IC95%: 52,0-58,3), con p<0,05. Conclusión La relativamente baja aceptación de la vacunación contra la COVID-19 en Colombia plantea retos importantes para lograr el control de la pandemia. Objective Colombia designed and adopted a vaccination plan against COVID-19 that will immunize 35 million people. The study aim was to detect the level of willingness to accept vaccination against COVID-19. Methods A telephone survey of 11,721 people aged 80 and over, affiliated with a health insurer, was carried out. The respondents were the affiliates or their relatives or caregivers. Results The average age was 85.0 years (SD: 4.5), with no differences between sexes;3,344 (28.5%) referred to a previous diagnostic test for COVID-19 and 73 were positive, giving an incidence of 622.8 per 100,000 people (95% CI: 491-778). Regarding attitude to vaccination against SARS-CoV-2, 1/4 respondents refrained from giving an opinion or were neutral. When the respondent was a relative, the acceptance of the vaccine was 60.4% (95% CI: 59.5-61.3) with differences by gender: men 62.2% (95% CI: 60.8-63.6) and women 59.2 (95% CI: 58.0-60.3), P<.05. When the respondent was the potential recipient of the vaccine, the acceptance of the vaccine was 61.7% (95% CI: 59.4-64.0) and this also differed by gender: 70.2% in men (95% CI: 66, 9-73.5) and 55.1% in women (95% CI: 52.0-58.3), P<.05. Conclusion The relatively low acceptance of vaccination against COVID-19 in Colombia poses significant challenges to achieve herd immunity that would allow control of the pandemic.

3.
Vacunas ; 23: S41-S45, 2022 May.
Article in Spanish | MEDLINE | ID: covidwho-1466956

ABSTRACT

Objective: Colombia designed and adopted a vaccination plan against COVID-19 that will immunize 35 million people. The aim study was to know the willingness to accept the vaccination against COVID-19. Methods: A telephone survey of 11,721 people aged 80 and over, affiliated with a health insurer, was carried. The respondents were the affiliates or their relatives or caregivers. Results: The average age was 85.0 years (SD: 4.5), with no differences between sexes; 3,344 (28.5%) referred a previous diagnostic test for COVID-19 and 73 were positive for an incidence of 622.8 per 100,000 people (95%CI: 491-778). Regarding the attitude with the vaccination against SARS-CoV-2, 1/4 respondents refrained from giving an opinion or was neutral. When the respondent was a relative, the acceptance of the vaccine was 60.4% (95% CI: 59.5-61.3) with differences by gender: men 62.2% (95% CI: 60.8-63.6) and women of 59.2 (95% CI: 58.0-60.3), P < 0.05. When the respondent was the potential recipient of the vaccine, the acceptance of the vaccine was 61.7% (95% CI: 59.4-64.0) and also differed by gender: 70.2% in men (95% CI: 66, 9-73.5) and 55.1% in women (95% CI: 52.0-58.3), P < 0.05. Conclusion: The relatively low acceptance of vaccination against COVID-19 in Colombia poses significant challenges to achieve herd immunity that allows control of the pandemic.

SELECTION OF CITATIONS
SEARCH DETAIL